She trained as a brewmaster. Nobody would hire her as one, because she was a woman. So in 1978 Kiran Mazumdar-Shaw started Biocon instead, with very little money and a plan that began in industrial enzymes and moved steadily toward medicine.
It worked. Decades later Biocon is one of India's most important biotechnology companies, making affordable insulin, biosimilars and cancer therapies for markets the global pharmaceutical industry had quietly priced out.
Affordable innovation, she insisted, was not a contradiction — it was the entire point.
Her argument, made loudly and for years, was that India could compete in science-intensive industries rather than only in services — and that innovation and affordability were not opposites. She has stayed a public voice on healthcare, research funding and the position of women in science.
From a garage operation to a global biopharma group is a long way to travel. It also built an industry that did not meaningfully exist in India when she started, which is the part that outlives any single company.